Circulating microparticles: pathophysiology and clinical implications - PubMed (original) (raw)
Review
Circulating microparticles: pathophysiology and clinical implications
Andrea Piccin et al. Blood Rev. 2007 May.
Abstract
Microparticles (MP) derived from vascular endothelium or circulating blood cells circulate in the peripheral blood. They originate from blebbing and shedding from cell membrane surfaces in physiological and pathological conditions and are present in low concentrations in normal plasma. Increased levels are generated by a number of mechanisms including platelet activation, direct vascular endothelial damage, thrombin activity on the cell surface, C5b-9 activation, and PF4-heparin-antibody interaction. Several techniques are currently used to study the generation and nature of circulating microparticles. In particular, the genesis and role of microparticles, derived from platelets, endothelial cells and monocytes, in sepsis (especially meningococcal-induced), heparin-induced thrombocytopenia (HIT), thrombotic thrombocytopenic purpura (TTP), aplastic anaemia, paroxysmal nocturnal haemoglobinuria (PNH) and sickle cell disease (SCD) have been well studied, and provide important insights into the underlying diseases. A defect in the ability to form microparticles leads to the severe bleeding disorder of Scott syndrome, which in turn provides a revealing insight into the physiology of coagulation. In addition the complex role of microparticles in vascular and cardiovascular diseases is an area of immense interest, that promises to yield important advances into diagnosis and therapy.
Similar articles
- Elevated circulating endothelial membrane microparticles in paroxysmal nocturnal haemoglobinuria.
Simak J, Holada K, Risitano AM, Zivny JH, Young NS, Vostal JG. Simak J, et al. Br J Haematol. 2004 Jun;125(6):804-13. doi: 10.1111/j.1365-2141.2004.04974.x. Br J Haematol. 2004. PMID: 15180871 - Platelet microparticles and vascular cells interactions: a checkpoint between the haemostatic and thrombotic responses.
Morel O, Morel N, Freyssinet JM, Toti F. Morel O, et al. Platelets. 2008 Feb;19(1):9-23. doi: 10.1080/09537100701817232. Platelets. 2008. PMID: 18231934 Review. - Plasma microparticles and vascular disorders.
Lynch SF, Ludlam CA. Lynch SF, et al. Br J Haematol. 2007 Apr;137(1):36-48. doi: 10.1111/j.1365-2141.2007.06514.x. Br J Haematol. 2007. PMID: 17359370 Review. - Circulating endothelial microparticles are associated with vascular dysfunction in patients with end-stage renal failure.
Amabile N, Guérin AP, Leroyer A, Mallat Z, Nguyen C, Boddaert J, London GM, Tedgui A, Boulanger CM. Amabile N, et al. J Am Soc Nephrol. 2005 Nov;16(11):3381-8. doi: 10.1681/ASN.2005050535. Epub 2005 Sep 28. J Am Soc Nephrol. 2005. PMID: 16192427 - [Cellular microparticles and blood-vessel damage. I. Structure, detection and origin].
Diamant M, Tushuizen ME, Sturk A, Nieuwland R. Diamant M, et al. Ned Tijdschr Geneeskd. 2004 Jul 10;148(28):1376-80. Ned Tijdschr Geneeskd. 2004. PMID: 15291418 Review. Dutch.
Cited by
- Impact of lysosome status on extracellular vesicle content and release.
Eitan E, Suire C, Zhang S, Mattson MP. Eitan E, et al. Ageing Res Rev. 2016 Dec;32:65-74. doi: 10.1016/j.arr.2016.05.001. Epub 2016 May 26. Ageing Res Rev. 2016. PMID: 27238186 Free PMC article. Review. - Molecular characterisation of plasma membrane-derived vesicles.
Antwi-Baffour SS. Antwi-Baffour SS. J Biomed Sci. 2015 Aug 11;22(1):68. doi: 10.1186/s12929-015-0174-7. J Biomed Sci. 2015. PMID: 26259622 Free PMC article. Review. - Microvesicles/exosomes as potential novel biomarkers of metabolic diseases.
Müller G. Müller G. Diabetes Metab Syndr Obes. 2012;5:247-82. doi: 10.2147/DMSO.S32923. Epub 2012 Aug 7. Diabetes Metab Syndr Obes. 2012. PMID: 22924003 Free PMC article. - Increased levels of circulating microparticles in primary Sjögren's syndrome, systemic lupus erythematosus and rheumatoid arthritis and relation with disease activity.
Sellam J, Proulle V, Jüngel A, Ittah M, Miceli Richard C, Gottenberg JE, Toti F, Benessiano J, Gay S, Freyssinet JM, Mariette X. Sellam J, et al. Arthritis Res Ther. 2009;11(5):R156. doi: 10.1186/ar2833. Epub 2009 Oct 15. Arthritis Res Ther. 2009. PMID: 19832990 Free PMC article. - Exosomal PD-L1 predicts response with immunotherapy in NSCLC patients.
Wang Y, Niu X, Cheng Y, Zhang Y, Xia L, Xia W, Lu S. Wang Y, et al. Clin Exp Immunol. 2022 Jun 23;208(3):316-322. doi: 10.1093/cei/uxac045. Clin Exp Immunol. 2022. PMID: 35514075 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous